^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Dihydrofolic acid reductase inhibitor

2d
Isolated β-Human Chorionic Gonadotropin Elevation-From Pregnancy to Fragile X-associated Premature Ovarian Insufficiency. (PubMed, AACE Endocrinol Diabetes)
After removal of the IUD and methotrexate therapy for presumed ectopic pregnancy in an unknown location, β-HCG level remained elevated...Hormone therapy with oral estradiol 2 mg daily and cyclic oral micronized progesterone 200 mg on 12 days of each month was initiated...After pregnancy has been ruled out, less common causes of β-HCG elevations like gestational trophoblastic disease, germ cell tumors, POI associated menopause, and heterophile antibody interference, should be evaluated. FXPOI should be considered in young patients with β-HCG elevation.
Journal
|
FMR1 (Fragile X Messenger Ribonucleoprotein 1)
|
methotrexate
4d
Chitosan-quercetin complex containing nanospheres for targeted delivery of methotrexate against MCF-7 breast cancer cells. (PubMed, Int J Biol Macromol)
CS-QT-PCL-MTX-Ns at a concentration of 120 μg/mL at 72 h which was 14 ± 2.0% exhibited dose dependent cytotoxicity against MCF-7 breast cancer cells with PDI < 0.5. Conclusively, CH-Qt-PCL-MTX-Ns demonstrate promising potential for the management of breast cancer along with enhanced anti-inflammatory effect.
Journal
|
HMGB1 (High Mobility Group Box 1)
|
methotrexate
5d
Identification of hub genes and lncRNAs driving the transition from early response to methotrexate resistance in HT29 colon cancer cells. (PubMed, Biochem Pharmacol)
MALAT1 and NEAT1 were overexpressed and identified as lncRNA hubs, whereas H19 displayed a dual expression pattern, overexpressed in sensitive cells 48 h post-MTX exposure but underexpressed in resistant cells. Our findings support the involvement of these lncRNAs and CAV1 in the early transcriptional response to MTX in colorectal cancer cells.
Journal
|
CAV1 (Caveolin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • H19 (H19 Imprinted Maternally Expressed Transcript)
|
methotrexate
5d
IL-16 in Vitreoretinal Lymphoma: First Vitreous Detection and a Preliminary Longitudinal Observation. (PubMed, Ocul Immunol Inflamm)
A patient with biopsy-proven VRL underwent longitudinal vitreous cytokine analysis during intravitreal methotrexate (MTX) and dexamethasone (DEX) therapy. Co-expression of IL-10 and IL-May 16, reflect a dynamic interaction between lymphoma cells and the TME, contributing to immune modulation and treatment resistance. Longitudinal IL-16 monitoring may provide additional insight into disease activity and therapeutic response; however, this requires validation in larger VRL cohorts, ideally including inflammatory controls.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL16 (Interleukin 16)
|
methotrexate • dexamethasone
6d
Placoid Macular Lesion as an Atypical Presentation of Vitreoretinal Lymphoma Mimicking Autoimmune Retinopathy. (PubMed, Ocul Immunol Inflamm)
The patient was successfully treated with intravitreal methotrexate and systemic chemotherapy followed by consolidative low-dose radiotherapy...Extended latency periods between central nervous system involvement and ocular manifestations are possible, potentially longer than previously reported. CSF analysis for MYD88 mutation and IL-10/IL-6 ratio provides crucial diagnostic value when vitreous sampling is inconclusive, emphasizing the importance of multi-parametric liquid biopsy approaches in challenging VRL cases.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL10 (Interleukin 10) • IL6R (Interleukin 6 receptor)
|
methotrexate
6d
CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate. (PubMed, J Clin Exp Hematop)
Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions.
Journal • IO biomarker
|
BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD79A (CD79a Molecule) • ICOSLG (Inducible T Cell Costimulator Ligand) • CD40 (CD40 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL1R1 (Interleukin 1 receptor, type I) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
|
nCounter® PanCancer Immune Profiling Panel
|
methotrexate
6d
Clinical outcomes and MRI-based neurotoxicity assessment of elderly primary CNS lymphoma. (PubMed, J Clin Neurosci)
In elderly PCNSL patients, R-MPV without routine WBRT provides effective disease control while being associated with less structural brain change. CSF IL-10 may represent a potential biomarker of susceptibility to treatment-related brain structural alterations.
Clinical data • Journal
|
IL10 (Interleukin 10)
|
methotrexate • methotrexate IV
7d
Enzymatically-modified isoquercitrin alleviates skin inflammation, mast cell degranulation, and vascular hyperpermeability in a mouse model of plaque psoriasis. (PubMed, Int Immunopharmacol)
Therefore, this work aimed to evaluate the potential effect of enzymatically-modified isoquercitrin (EMIQ, 50 and 100 mg/kg body weight "b.wt", administered orally for 8 days), in comparison with methotrexate (MTX, a synthetic drug), against imiquimod (IMQ)-induced psoriatic lesions in female BALB/c mice. Moreover, oral administration of EMIQ prevented significantly (P < 0.001) the vascular permeability associated with augmented Evans blue leakage and dermal accumulation of degranulated mast cells, suggesting a reduction in inflammation and edema. Taken together, our study demonstrated that EMIQ can alleviate psoriasis and may be considered as a promising strategy for psoriasis treatment via targeting IL-23/IL-17A axis and mast cell degranulation.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta)
|
methotrexate • Zyclara (imiquimod)
11d
Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort. (PubMed, Biomedicines)
Therapeutic management followed an early, aggressive strategy, frequently utilizing cyclophosphamide (45.8%) and methotrexate (37.5%), with Janus kinase (JAK) inhibitors or rituximab employed in refractory cases. The observed dissociation between low CK/CRP and elevated LDH underscores the necessity for a high index of suspicion, with LDH serving as a superior marker for disease activity. While ILD presents a significant risk, early and intensive multi-modal intervention may yield superior survival outcomes in European patients compared to the historical mortality rates reported in Asian cohorts.
Clinical • Journal
|
IFIH1 (Interferon Induced With Helicase C Domain 1) • CRP (C-reactive protein)
|
LDH elevation
|
Rituxan (rituximab) • cyclophosphamide • methotrexate
11d
Anti-Inflammatory Effects of Curcumin via the Nrf2-cGAS-STING-NF-κB Pathway in MH7A Rheumatoid Arthritis Fibroblast-like Synoviocytes. (PubMed, Biomedicines)
Groups included a control group, a model group, a methotrexate positive control group [MTX(methotrexate), 10 μmol/L], and curcumin treatment groups at varying concentrations (10-100 μmol/L)... Curcumin (CUR) can effectively inhibit the inflammatory response of synovial fibroblasts by activating the expression of NRF2 and subsequently suppressing the cGAS-STING-NF-κB signaling pathway. This study provides a new molecular mechanism target for curcumin in the treatment of RA and offers a theoretical basis for the intervention of autoimmune diseases with natural products.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
|
methotrexate
11d
Bioinformatic Analysis of microRNAs Associated with Chemotherapy-Induced Cognitive Impairment: Integration of Gene Networks and Neuroinflammatory Pathways. (PubMed, Biomedicines)
Six experimental studies using animal models were selected, which showed that agents such as doxorubicin, cisplatin, and methotrexate induce changes in domains such as memory, attention, and learning. These findings suggest that miRNAs play a central role in mediating the observed neurocognitive changes and may represent promising biomarkers and therapeutic targets to mitigate the effects of chemobrain. The study also highlights the need for future research integrating molecular and behavioral analyses to achieve more precise clinical applications.
Journal
|
MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21)
|
cisplatin • doxorubicin hydrochloride • methotrexate
12d
Therapeutic potential of interleukin-33 blockade in mitigating synovial inflammation and cartilage damage. (PubMed, Scand J Rheumatol)
The CIA model was established in DBA/1 mice, which were treated with anti-IL-33, methotrexate, or vehicle...IL-33 blockade effectively mitigates synovial inflammation and joint destruction by suppressing the proliferation, migration, and invasion of RA-FLSs while promoting their apoptosis. Targeting IL-33 may represent a promising strategy for the treatment of rheumatoid arthritis.
Journal
|
IL6 (Interleukin 6) • IL33 (Interleukin 33)
|
methotrexate